| Literature DB >> 31692341 |
Michael T Davenport1, Jordan A Dickson1, Matthew R Johnson1, Stephen Chamberland1.
Abstract
The first total synthesis of clavatadine B (2), a natural product found to be a selective human blood coagulation factor XIa inhibitor, is described. A convergent approach that exemplifies the advantages of direct, early stage guanidinylation provided an immediate clavatadine B precursor, which was assembled in an efficient manner using known synthetic precursors of the structurally related natural product clavatadine A (1). Global deprotection cleanly provided clavatadine B in only four steps from a known derivative of homogentisic acid lactone (longest linear sequence, 75% overall yield).Entities:
Mesh:
Substances:
Year: 2019 PMID: 31692341 DOI: 10.1021/acs.jnatprod.9b00813
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050